Skylands Capital LLC grew its stake in shares of QuidelOrtho Corporation (NASDAQ:QDEL – Free Report) by 153.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 341,554 shares of the company’s stock after purchasing an additional 206,850 shares during the quarter. Skylands Capital LLC owned approximately 0.50% of QuidelOrtho worth $5,612,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in QDEL. Hantz Financial Services Inc. grew its stake in QuidelOrtho by 50.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,082 shares of the company’s stock worth $31,000 after buying an additional 362 shares during the last quarter. ProShare Advisors LLC lifted its stake in QuidelOrtho by 3.0% in the fourth quarter. ProShare Advisors LLC now owns 13,164 shares of the company’s stock valued at $376,000 after buying an additional 388 shares during the last quarter. State of Alaska Department of Revenue boosted its holdings in shares of QuidelOrtho by 1.1% during the fourth quarter. State of Alaska Department of Revenue now owns 38,333 shares of the company’s stock valued at $1,093,000 after acquiring an additional 424 shares during the period. Moody National Bank Trust Division boosted its holdings in shares of QuidelOrtho by 1.0% during the fourth quarter. Moody National Bank Trust Division now owns 51,512 shares of the company’s stock valued at $1,471,000 after acquiring an additional 526 shares during the period. Finally, California State Teachers Retirement System grew its position in shares of QuidelOrtho by 1.2% during the second quarter. California State Teachers Retirement System now owns 62,188 shares of the company’s stock worth $1,792,000 after acquiring an additional 725 shares during the last quarter. 99.00% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several equities research analysts have commented on QDEL shares. Weiss Ratings restated a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Wall Street Zen raised shares of QuidelOrtho from a “sell” rating to a “hold” rating in a report on Sunday. Zacks Research upgraded shares of QuidelOrtho from a “strong sell” rating to a “hold” rating in a report on Monday, June 15th. Citigroup reduced their target price on shares of QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th. Finally, UBS Group restated a “neutral” rating and issued a $12.00 price target on shares of QuidelOrtho in a research report on Thursday, May 7th. Four equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average target price of $14.88.
QuidelOrtho Stock Performance
QDEL opened at $13.79 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. The stock’s 50 day moving average price is $12.49 and its two-hundred day moving average price is $20.31. The firm has a market capitalization of $940.34 million, a P/E ratio of -0.77 and a beta of 0.77. QuidelOrtho Corporation has a 12-month low of $9.92 and a 12-month high of $35.58.
QuidelOrtho (NASDAQ:QDEL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The business had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. During the same period in the prior year, the company posted $0.74 earnings per share. The firm’s revenue was down 10.5% compared to the same quarter last year. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, equities analysts forecast that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.
About QuidelOrtho
QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.
The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.
Further Reading
- Five stocks we like better than QuidelOrtho
- 3 Stocks That Could Benefit as the Robotaxi Race Heats Up
- 3 Waste Stocks Turning AI Investments into Growth
- 3 Overlooked Tech ETFs That Are Quietly Killing It This Year
- 3 ETFs Pairing Market-Beating Returns With High Dividend Yields
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.
